CRIS Curis, Inc.
Curis, Inc. (CRIS) is expected to report earnings on November 13, 2026, after the market close. The consensus earnings estimate is a loss of $5.87 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.6% since its last earnings release on August 14, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Curis, Inc.
Curis Inc is a biotechnology company engaged in developing and commercializing drug candidates for the treatment of human cancers. Its products include CUDC-907, phosphatidylinositol-3-kinase and small molecule inhibitor of histone deacetylase.
Sector
Healthcare
Industry
Biotechnology